Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus guselkumab-hoidon jatkuvuudesta nivelpsoriaasipotilailla (PEGASUS)

maanantai 2. marraskuuta 2026 päivittänyt: Janssen-Cilag Ltd.

Todellisen maailman prospektiivinen tutkimus guselkumabin hoidon jatkuvuudesta nivelpsoriaasipotilailla

This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

200

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Lille, Ranska, 59037
        • Rekrytointi
        • Hopital Roger Salengro - CHU Lille

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

The study population will include participants affected with psoriatic arthritis (PsA) according to classification for psoriatic arthritis (CASPAR) criteria.

Kuvaus

Inclusion criteria:

  • Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
  • Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
  • Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
  • Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements

Exclusion Criteria:

  • Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.
  • Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase [JAK] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
  • Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
  • Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Group 1: Psoriatic Arthritis Participants Treated With Guselkumab

Participants with confirmed diagnosis of psoriatic arthritis treated with guselkumab as per routine clinical practice will be enrolled. No drug will be provided as part of this study. Only data available within routine clinical practice will be collected in this study.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Proportion of Participants Still Receiving Treatment at 1 Year
Aikaikkuna: At 1 year

Discontinuation or maintenance of guselkumab treatment will be recorded by the physician at each visit. Proportion of participants still receiving treatment will be reported in the outcome measure.

At 1 year
Percentage of Participants Still Receiving Treatment at Persistence Time
Aikaikkuna: Up to 8 weeks

Persistence time of the initial treatment: defined as the time from the date of the first administration of guselkumab to the date that the last dose of guselkumab treatment was administered plus 1 dosing interval (8 weeks), or until start of subsequent treatment.

Up to 8 weeks
Number of Participants Starting New Treatment
Aikaikkuna: At 1 year

Participants starting new treatment along with reason of discontinuation will be reported.

At 1 year

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percentage of Participants Still Receiving Treatment at 2 years
Aikaikkuna: At 2 years

Percentage of participants still receiving treatment at 2 years will be reported.

At 2 years
Percentage of Participants Discontinuing The Treatment
Aikaikkuna: At 2 years

Participants discontinuing the treatment along with the reasons will be reported.

At 2 years
Change From Baseline in Disease Activity Index in Psoriatic Arthritis (DAPSA)/ Clinical Disease Activity Index in Psoriatic Arthritis (cDAPSA)
Aikaikkuna: Baseline, Months 3,6,12,18, and 24

The DAPSA was developed to characterize psoriatic arthritis (PsA) disease activity. It considers the number of painful and swollen joints, the patient's assessment of their disease and the C-reactive protein (CRP) measurement for acute inflammation. Where CRP measurements are not available, the clinical DAPSA (cDAPSA) maybe be used, which omits CRP. An overall score is calculated, where higher scores correspond to higher disease activity. Cut-off values for DAPSA low and high disease activity are: ≤14 and >28 points, respectively, and for remission is ≤4 points. The cut-off values for cDAPSA are: ≤4 points for remission, >4 to ≤13 points for low disease activity, > 13 to ≤27 points for moderate disease activity, and >27 points for high disease activity.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Leeds Enthesitis Index (LEI) Score
Aikaikkuna: Baseline, Months 3,6,12,18, and 24

The Leeds enthesitis index (LEI) measures the activity of enthesitis in PsA. The index measures the severity and activity of enthesitis, inflammation at the attachment of the ligaments and tendons to bone. The clinical assessor must elicit tenderness at 6 enthesitis sites: both lateral epicondyles of the humerus, both medial condyles of the femur, and the Achilles tendon insertions. Each site affected is summed to give a score out of 6, where 6 indicates all sites affected.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Back and Neck Pain Numerical Rating Scale (NRS) Score
Aikaikkuna: Baseline, Months 3,6,12,18, and 24

NRS for back and neck pain will be administered. This is a simple numbered 0-10 scale on which the patient indicates the intensity of their pain (0 represents no pain and 10 indicates the worst possible pain).

Baseline, Months 3,6,12,18, and 24
Hazard Ratios Between Baseline Clinical Factors and Guselkumab Persistence and Effectiveness at Months 12 and 24
Aikaikkuna: At Month 12 and 24

Hazard ratios for association between baseline clinical factors and persistence/effectiveness from Cox proportional hazards models will be reported.

At Month 12 and 24
Sociodemographic Characteristics: Age
Aikaikkuna: At Baseline

Participant's age will be reported.

At Baseline
Sociodemographic Characteristics: Sex
Aikaikkuna: At Baseline

Participant's sex (male, female) will be reported

At Baseline
Sociodemographic Characteristics: Weight
Aikaikkuna: At Baseline

Participant's weight will be reported

At Baseline
Sociodemographic Characteristics: Height
Aikaikkuna: At Baseline

Participant's height will be reported.

At Baseline
Sociodemographic Characteristics: Body Mass Index (BMI)
Aikaikkuna: At Baseline

Participant's BMI will be reported.

At Baseline
Number of Participants Reporting Smoking, Cannabis and Alcohol Use
Aikaikkuna: At Baseline

Participant's smoking, use of Cannabis and Alcohol habit will be reported.

At Baseline
Number of Participants With Family History of Psoriasis and/or Psoriatic Arthritis and/or Spondyloarthritis
Aikaikkuna: At Baseline

Family history of psoriasis and/or psoriatic arthritis and/or spondyloarthritis wil be reported.

At Baseline
Date of Diagnosis of Psoriatic Arthritis
Aikaikkuna: At Baseline

Date of diagnosis of psoriatic arthritis will be reported.

At Baseline
Date of Previous Treatments of Psoriatic Arthritis
Aikaikkuna: At Baseline

Date of previous treatments of psoriatic arthritis will be reported.

At Baseline
Duration of Previous Treatments of Psoriatic Arthritis
Aikaikkuna: At Baseline

Duration of previous treatments of psoriatic arthritis will be reported.

At Baseline
Medical History and Current Situation
Aikaikkuna: At Baseline

Participants medical history and current medical situation will be reported.

At Baseline
Number of Participants Receiving Co-occurring Treatments Linked to Psoriatic Arthritis
Aikaikkuna: Baseline up to 2 Years

Participants receiving co-occurring treatments linked to psoriatic arthritis at baseline and during follow-up will be reported.

Baseline up to 2 Years
Failure to Achieve or Maintain Response
Aikaikkuna: Up to 2 Years

Failure to achieve or maintain response to at least 2 biologic/targeted synthetic DMARDs with at least 2 different mechanisms of action (Y/N) (For treatment refractory criteria).

Up to 2 Years
Number of Participants Reporting Problems Related to the Management of Signs and Symptoms
Aikaikkuna: At baseline

The management of signs and/or symptoms that is perceived as problematic by the rheumatologist and/or the participants will be reported.

At baseline
Evidence of Persistent Disease
Aikaikkuna: Up to 2 Years

Evidence of persistent disease as defined by at least 2 of the following: a) failure to achieve or maintain low disease activity, b) the presence of active extra-musculoskeletal manifestations of PsA, c) objective evidence of inflammatory activity, namely clinical signs, elevated acute phase reactants and/or imaging findings suggestive of inflammation.

Up to 2 Years
Number of Participants with Co-Morbidities
Aikaikkuna: At baseline

Number of participants with co-morbidities will be reported.

At baseline
Number of Participants with Abnormal Psychosocial Factors
Aikaikkuna: At Baseline

Number of participants with abnormal psychosocial factors will be reported.

At Baseline
Healthcare Professional (HCP): Age Group
Aikaikkuna: At Baseline

Age group of HCP will be reported.

At Baseline
HCP: Sex
Aikaikkuna: At Baseline

Sex of HCP will be reported.

At Baseline
HCP: Experience
Aikaikkuna: At Baseline

Experience of HCP will be reported.

At Baseline
HCP: Type of Practice
Aikaikkuna: At Baseline

Type of practice of HCP will be reported.

At Baseline
Number of Participants With Adverse Events, Serious Adverse Events, Infections and Injection Site Reactions
Aikaikkuna: Up to 2 Years

AEs with onset or worsening on or after date of first dose of study treatment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1 equal (=) Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE. SAE is any untoward medical occurrence that results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Up to 2 Years
Tolerance Related Guselkumab Treatment
Aikaikkuna: Up to 2 Years

Tolerance Related guselkumab treatment will be reported.

Up to 2 Years
Dose at Initiation of Guselkumab
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Dose at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Treatment Interval at Initiation of Guselkumab
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Treatment interval at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Type of Injection
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Type of injection will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Reporting Change of Injection Frequency
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Participants reporting change of injection frequency (Q4 to Q8 or Q8 to Q4) and its reason will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participant With Co-occurring Treatments Linked to PSA
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Participants with co-occurring treatments linked to PSA will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants With Reason for Choosing Guselkumab From the Therapeutic Arsenal
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Participants with reason for choosing guselkumab from the therapeutic arsenal will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Switching to New Treatment in Case of Discontinuation of Guselkumab Treatment
Aikaikkuna: At Months 0, 3, 6, 12, 18 and 24

Participants switching to new treatment in case of discontinuation of guselkumab treatment will be reported.

At Months 0, 3, 6, 12, 18 and 24
Change From Baseline in 12-item Psoriatic Arthritis Impact of Disease Questionnaire (PsAID-12) Questionnaire Score
Aikaikkuna: Baseline, Months 0, 3, 6, 12, 18 and 24

The PsAID-12 questionnaire was designed to assess the impact of disease, with questions on pain, physical function, fatigue, coping and depression. It is a validated, self-administered questionnaire developed for use in clinical practice that assesses the impact of PsA on patients' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline, Months 0, 3, 6, 12, 18 and 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Each Visit After Baseline
Aikaikkuna: Baseline, Months 0, 3, 6, 12, 18 and 24

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was developed to measure disease activity in patients with ankylosing spondylitis. It consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration and morning stiffness severity. Each symptom is assessed on a scale of 0-10 where 0 indicates no pain or discomfort and 10 indicates maximum pain or discomfort. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease.

Baseline, Months 0, 3, 6, 12, 18 and 24
Satisfaction of Treatment for the Participants
Aikaikkuna: At Months 3, 6, 12, 18 and 24

The satisfaction of treatment for the participant will be assessed using a 5-point Likert scale, ("Very dissatisfied Dissatisfied Neither satisfied nor dissatisfied Satisfied Very satisfied"). The scale includes two patient reported questions: "1) How satisfied or dissatisfied are you with the overall convenience of this medication" and "2) How satisfied or dissatisfied are you with the ability of this medication ability to treat your condition?" Scores range from Very dissatisfied to Very satisfied and will be used to evaluate satisfaction with guselkumab treatment.

At Months 3, 6, 12, 18 and 24
Satisfaction of Treatment Care Management and Patient Relationship for the Rheumatologist
Aikaikkuna: At Months 3, 6, 12, 18 and 24

Satisfaction of treatment care management and patient relationship for the rheumatologist will be assessed using a 5-point Likert scale specified as : "Very dissatisfied, Dissatisfied, Neither satisfied nor dissatisfied, Satisfied and Very satisfied." The physician-reported questions are: "1) How satisfied or dissatisfied are you with this drug overall for this patient?" and "2) How satisfied or dissatisfied are you with the ease of managing your patient with guselkumab?"

At Months 3, 6, 12, 18 and 24

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Janssen-Cilag France Clinical Trial, Janssen-Cilag France

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 17. huhtikuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 10. joulukuuta 2029

Opintojen valmistuminen (Arvioitu)

Maanantai 10. joulukuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 8. huhtikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 8. huhtikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 15. huhtikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 3. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • CNTO1959PSA4021
  • CNTO1959PSA4021 (Muu tunniste: Janssen Research & Development, LLC)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .